Biologics News

Study findings showed fibrin glue to be an effective scaffold for mesenchymal stem cell implantation when treating patients with osteoarthritic knees.

In a 2-year study examining the use of i-FACTOR bone graft material in posterior lumbar interbody fusion, researchers found the alternative material had equal or greater efficacy at 6 and 12 months compared with autograft.

Researchers have identified a previously unknown beneficial immune response that occurs after injury to the central nervous system, according to a press release from the University of Virginia Health System.

Nonvascularized structural corticocancellous bone grafting performed with bone from the olecranon showed some advantages over bone from the iliac crest for the treatment of large segmental bone defects of the phalanges, according to findings from a recently published case report.

Orthopedics Today has put together a compilation of the five news stories and videos most viewed from January 2015 to keep you abreast of the current hot topics in orthopedics.

A proof-of-concept clinical trial was launched by surgeons at UC Davis to test the safety and efficacy of a device that can concentrate and extract young cells from the irrigation fluid used during orthopedic surgery, possibly improving the delivery of stem cell therapies in cases of non-healing fractures.

Bone Therapeutics recently announced it will undertake efforts to expand its offerings to include osteoblastic cell-matrix products. These offerings, which will be used to treat large bone defects, will be a variant of the company’s osteoblastic cells within a 3-D bioprinted scaffold. The company believes this will become a favorable alternative to the current standard of care, bone autograft, according to a press release.

Integra LifeSciences recently announced the acquisition of biologics and foot and ankle product offerings from Metasurg.

Orthopedics Today features eight stories and videos of importance to emerge from the Orthopedics Today Hawaii 2015 meeting.

Subsequent applications of platelet-rich plasma have been shown to be less effective than the initial application on the proliferation of human tenocytes in a recently published in vitro study.